Sequenom, Inc. (SQNM) Tops Q1 EPS by 1c

Sequenom, Inc. (NASDAQ: SQNM) reported Q1 EPS of ($0.13), $0.01 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $46.3 million versus the consensus estimate of $46.06 million.

Total laboratory test volume increased to nearly 50,000 tests accessioned in the first quarter of 2014, including 39,800 MaterniT21™ PLUS tests.

"We are pleased with the continued growth and 8% sequential increase in MaterniT21 PLUS tests, especially as we focus on building more profitable test volume," said Harry F. Hixson, Jr., Ph.D., Chairman and CEO of Sequenom. "We continue to make progress within the payor community, bringing the current number of lives covered under commercial signed contracts to 118 million and government programs to 24 million."

For earnings history and earnings-related data on Sequenom, Inc. (SQNM) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• zSpace, Inc. (ZSPC) Reports Q2 results
• Boston Omaha Corporation (BOC) Misses Q2 EPS by 2c